HemaSure seeks approval of blood filter:
This article was originally published in Clinica
HemaSure has filed a 510(k) application with the FDA to market its r/LS red blood cell filter in the US. The filter removes white blood cells (leukocytes) from red blood cell concentrates and in doing so reduces the risk of transmission of viruses on the back of leukocytes such as Hepatitis B and C and Epstein Barr virus. It is designed to be used for high volumes of blood where there is a need for cost effectiveness. The Marlborough, Massachusetts-based company has already CE-marked the filter.